Late-stage pipeline products could generate $5.4b in sales across the 7MM.

Late-stage pipeline products could generate $5.4b in sales across the 7MM. The late-stage pipeline products will drive combined sales of approximately $5.4b by 2035 in the 7MM, with DMTs expected to account for about a quarter of those sales. Three of the 12 late-stage pipeline products are being developed as DMTs, aiming to address the underlying causes of epilepsy. “There are several pipeline therapies that also operate on synaptic mechanisms, and although demonstrating potential, are likely to encounter similar issues as currently marketed therapies.” He added that although cheap generic drugs remain a major barrier to market growth, late-stage pipeline products, together with rising diagnosed prevalence, are expected to drive growth through 2035.